|XDATA – January 4th 2016|
|Akcea Therapeutics disclosed raising $543.17 million as part of a non-brokered equity private placement. One investor acquired the securities on December 18th. No offering was previously initiated by the company under a registration exemption with the SEC.
The issuance includes cash and non-cash consideration, including the grant of certain rights and licenses.
|The company is focused on the development and commercialization of Ionis Pharmaceuticals’ lipid portfolio of novel new medicines for the treatment of serious cardiometabolic lipid disorders. Established as. Investors include Ionis Pharmaceuticals.|
|The company was registered in 2015 and has its headquarters located in Cambridge MA. Akcea Therapeutics elected to keep its revenues undisclosed.
The executive team includes Elizabeth L Hougen, Jeffrey Goldberg, Patrick O’Neil, Paula Soteropoulos and Stanley T Crooke.
The board of directors includes B Lynne Parshall.
Company: Akcea Therapeutics
Amount offered: $543.17 million
Amount placed: $543.17 million
SEC filing: Source
First sale: 12-18-2015
Data as of: 01-04-2016